PCRC_A021502

Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

Key Eligibility
•Histologically proven stage III colon adenocarcinoma
•Presence of deficient (d) DNA mismatch repair (dMMR)
•Tumors must have been completely resected
•Entire tumor must be in the colon (rectal involvement is an exclusion)
•No evidence of residual involved lymph node disease or metastatic disease at the time of registration
Phase III
NCT02912559
Cancer
Gastrointestinal
Alison Conlin, M.D.
Alliance
Mary Mccormick

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.